Kronos Bio Inc’s recent filing unveils that its PRESIDENT & CEO BISCHOFBERGER NORBERT W acquired Company’s shares for reported $0.48 million on Jun 27 ’24. In the deal valued at $1.17 per share,410,848 shares were bought. As a result of this transaction, BISCHOFBERGER NORBERT W now holds 10,597,468 shares worth roughly $7.84 million.
Then, BISCHOFBERGER NORBERT W bought 204,670 shares, generating $254,957 in total proceeds. Upon buying the shares at $1.25, the PRESIDENT & CEO now owns 10,802,138 shares.
Before that, BISCHOFBERGER NORBERT W bought 1,378,901 shares. Kronos Bio Inc shares valued at $1,208,469 were divested by the PRESIDENT & CEO at a price of $0.88 per share. As a result of the transaction, BISCHOFBERGER NORBERT W now holds 5,749,395 shares, worth roughly $4.25 million.
TD Cowen downgraded its Kronos Bio Inc [KRON] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who decreased its forecast for the stock in mid November from “an Overweight” to “a Neutral”. Berenberg began covering KRON with “Buy” recommendation on September 14, 2022.
Price Performance Review of KRON
On Monday, Kronos Bio Inc [NASDAQ:KRON] saw its stock jump 2.56% to $0.74. Over the last five days, the stock has gained 1.26%. Kronos Bio Inc shares have fallen nearly -22.09% since the year began. Nevertheless, the stocks have fallen -28.84% over the past one year. While a 52-week high of $1.60 was reached on 01/23/25, a 52-week low of $0.67 was recorded on 05/01/25. SMA at 50 days reached $0.8475, while 200 days put it at $0.9527.
Levels Of Support And Resistance For KRON Stock
The 24-hour chart illustrates a support level at 0.7123, which if violated will result in even more drops to 0.6845. On the upside, there is a resistance level at 0.7540. A further resistance level may holdings at 0.7679. The Relative Strength Index (RSI) on the 14-day chart is 39.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0582, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.24%. Stochastics %K at 23.01% indicates the stock is a holding.
The most recent change occurred on June 24, 2021 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
